Extended Model‐Informed Drug Development: Beyond Clinical Trials and Regulatory Approval
Clinical Pharmacology & Therapeutics · 2024
DOI: 10.1002/cpt.3357 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Mohamed A Kamal und 3 weiteren Autor:innen. Beteiligte Einrichtung: Regeneron Pharmaceuticals, Tarrytown, New York, USA. Hauptthemen laut MEDLINE: Drug Development, Drug Approval, Clinical Trials as Topic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Regeneron Pharmaceuticals, Tarrytown, New York, USA.
- Certara, Princeton, New Jersey, USA.
Zitieren
APA
Kamal, M. A., Ganguly, S., Kadambi, A., & Smith, P. F. (2024). Extended Model‐Informed Drug Development: Beyond Clinical Trials and Regulatory Approval. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3357
Vancouver
Kamal MA, Ganguly S, Kadambi A, Smith PF. Extended Model‐Informed Drug Development: Beyond Clinical Trials and Regulatory Approval. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3357
BibTeX
@article{Kamal2024,
author = {Kamal, Mohamed A and Ganguly, Samit and Kadambi, Ananth and Smith, Patrick F},
title = {Extended Model‐Informed Drug Development: Beyond Clinical Trials and Regulatory Approval},
journal = {Clinical Pharmacology & Therapeutics},
year = {2024},
doi = {10.1002/cpt.3357}
}
EUVIMED